SINTX Technologies, Inc. SINT

Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited reve

Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other

SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. Gregg Honigblum, Chief Inve

SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintai

Moby summary of Sintx Technologies, Inc.'s Q2 2026 earnings call

SINTX Technologies Inc (SINT) reports strong product revenue growth and improved margins, while managing liquidity challenges and advancing its SINAPTIC medical platform.

SALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded

ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -31.03% and -16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SALT LAKE CITY, Utah, July 28, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m. ET to review the Company’s second quarter 2026 performance. Management participants

SALT LAKE CITY, Utah, July 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced biomaterials and silicon nitride technologies for medical device and industrial applications, today announced that it has engaged Southern Metrics Consulting (“Southern Metrics”) to assist the Company in identifying, evaluating, and pursuing strategic opportunities intended to enhance stockholder value. Southern Metrics is led by Chris Lyons, its Chief

SALT LAKE CITY, Utah, June 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it has received purchase orders from multiple contract manufacturing customers with an aggregate value exceeding $3.2 million for the production of advanced ceramic components. SINTX’s advanced ceramic manufacturing platform supports customers across multiple industries re

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

SALT LAKE CITY, Utah, June 03, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today announced that it has entered into securities purchase agreements with institutional and accredited investors pursuant to which the Company agreed to issue and sell an aggregate of 1,882,845 shares of common stock in a private placement priced at-the-market un

Salt Lake City, Utah--(Newsfile Corp. - May 17, 2026) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a medical technology company focused on advanced ceramics and silicon nitride biomaterials, today announced that management will present at the LD Micro Invitational XVI Conference in Los Angeles, California, at the Luxe Sunset Blvd Hotel.During the presentation, management expects to discuss recent progress in commercialization, product development, and manufacturing...

Sangamo (SGMO) delivered earnings and revenue surprises of -100.00% and -84.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -24.00% and +6.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?